arrow
Back
G

Ghulam Rehman Mohyuddin

University of Utah

18H-index
221Paper Count
1.3KCitation Count
Published Papers 62
Publication Date
Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma
err2026-07-14
err0
PREAI
errGhulam Rehman Mohyuddin; Edward R. Scheffer Cliff; Rajshekhar Chakraborty
errShare
errSave
Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review
err2026-07-09
err0
errOAAI
errGhulam Rehman Mohyuddin; Hector A. Vaquera-Alfaro; Amandeep Godara; Aaron Goodman; Maria Mainou; Rajshekhar Chakraborty; Hadas Ditzian Kugler; Tomer Meirson
errShare
errSave
Does ciltacabtagene autoleucel have a future in multiple myeloma?
err2026-06-08
err0
PREAI
errGhulam Rehman Mohyuddin; Edward R. Scheffer Cliff; Rajshekhar Chakraborty
errShare
errSave
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
err2026-06-07
err0
errOAAI
errGala Vega; Daniel Morillo; Christine Riedhammer; Febe Smits; Aishee Bag; Kelly Julian; Natalia Tovar Gomis; Carmen Montes Gaisan; Maria Aranzazu Bermudez; Mansi R. Shah; Ghulam Rehman Mohyuddin; Binod Dhakal; Leo Rasche; Carolina Schinke; Anita D'Souza; Aniko Szabo; Niels W. C. J. van de Donk; Rajshekhar Chakraborty; Meera Mohan
errShare
errSave
Improving Control Arms in 2026 U.S. Myeloma Trials
err2026-04-20
err0
errOAAI
errKathy L. Ding; Jacqueline Kunesh; Karun Neupane; Ghulam Rehman Mohyuddin
errShare
errSave
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis
err2026-04-01
err0
PREAI
errLemieux, Mackenzie; Chunara, Farheen; Szabo, Aniko; Van Oekelen, Oliver; Chakraborty, Rajshekhar; Godara, Amandeep; Shaikh, Hira; Strouse, Christopher; Mohan, Meera; Mohyuddin, Ghulam Rehman
errShare
errSave
Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study
err2026-02-26
err0
errOAAI
errMaria Mainou; Thomas Karagiannis; Eirini Pagkalidou; Aris Liakos; Panagiotis Malandrakis; Evdoxia Hatjiharissi; Sofia Chissan; Evdokia Mandala; Oliver Van Oekelen; Efthymia Vlachaki; Maria Papaioannou; Evangelos Terpos; Ghulam Rehman Mohyuddin; Apostolos Tsapas
errShare
errSave
Temporal trends in progression risk in smoldering myeloma: a systematic review
err2026-01-08
err0
errOAAI
errHeinz Ludwig; Efstathios Kastritis; Sarah Bernhard; Niels W.C.J. van de Donk; Mario Boccadoro; Evangelos Terpos; Pellegrino Musto; Pieter Sonneveld; Ghulam Rehman Mohyuddin
errShare
errSave
Why We Do Not Recommend That People With High-Risk Smoldering Myeloma Receive Treatment
err2025-12-01
err0
errOAAI
errMohyuddin, Ghulam Rehman; Lemieux, Mackenzie; Chakraborty, Rajshekhar; Gertz, Morie
errShare
errSave
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
err2025-11-09
err0
errOAAI
errMaria Mainou, MD; Muatassem Alsadhan, MD; Kalliopi Tsapa, MD; Alissa Visram, MD; Hira Mian, MD; Rakesh Popat, MD; Elias K Mai, MD; Rajshekhar Chakraborty, MD; Samer Al Hadidi, MD; Meera Mohan, MD; Aniko Szabo, PhD; Oliver Van Oekelen, MD; Edward R Scheffer Cliff, MBBS; Ghulam Rehman Mohyuddin, MD
errShare
errSave
The past, present, and future of myeloma staging and risk prognostication
err2025-10-01
err0
PREAI
errBaysal, Mehmet; Julian, Kelley; Sborov, Douglas; Godara, Amandeep; McClune, Brian; Lohr, Jens G.; Fortuna, Gliceida Galarza; Mohyuddin, Ghulam Rehman
errShare
errSave
Contextualizing results of randomized trials in smoldering myeloma
err2025-09-01
err0
PREAI
errMohyuddin, Ghulam Rehman; Goodman, Aaron M.; Chakraborty, Rajshekhar
errShare
errSave
Differences in adverse events between manuscript and drug labels for myeloma T-cell-redirecting therapies
err2025-07-27
err0
errOAAI
errBita Bashy; Darshi Shah; David Steensma; Oliver Van Oekelen; Rajshekhar Chakraborty; Ghulam Rehman Mohyuddin
errShare
errSave
Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies
err2025-07-22
err0
PREAI
errDarshi Shah; Veer Shah; Karan Shah; Prachi J. Shah; Muatassem Alsadhan; Alyson Haslam; Vinay Prasad; Muzaffar H. Qazilbash; Rajshekhar Chakraborty; Ghulam Rehman Mohyuddin
errShare
errSave
Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis
errLeukemia
IF13.4
err2025-07-16
err0
PREAI
errKritika Yadav; Meera Mohan; Charlotte Wagner; Rajshekhar Chakraborty; Douglas Sborov; Amandeep Godara; Brian McClune; Carolina Schinke; Binod Dhakal; Anita D’Souza; Aniko Szabo; Ghulam Rehman Mohyuddin
errShare
errSave
How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes
err2025-07-01
err1
errOAAI
errChahine, Zena; Meirson, Tomer; Gilboa, Shai; Mohyuddin, Ghulam Rehman
errShare
errSave
Guidance for discussants of randomized cancer trials at major meetings
err2025-05-01
err0
PREAI
errEisenhauer, Elizabeth A.; Abdihamid, Omar; Booth, Christopher M.; Cherny, Nathan; Fojo, Antonio T.; Gyawali, Bishal; Marini, Bernard L.; Mohyuddin, Ghulam Rehman; Pe, Madeline; Pond, Gregory R.; Soto-Perez-de-Celis, Enrique; Tannock, Ian F.; Trapani, Dario; Tregear, Michelle; van der Graaf, Winette T. A.; Wilson, Brooke E.
errShare
errSave
Prevalence of medical writing in hematological malignancy review articles
err2025-04-17
err0
errOAAI
errVaquera-Alfaro, Hector A.; Nasrollahi, Elham; Mangala, Yashvin Onkarappa; Russler-Germain, David; Goodman, Aaron; Mohyuddin, Ghulam Rehman
errShare
errSave
The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma
err2024-12-01
err0
errOAAI
errMohyuddin, Ghulam Rehman; Almasri, Jehad; Goodman, Aaron; Haslam, Alyson; Prasad, Vinay
errShare
errSave